Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
JAMA The Journal of the American Medical Association (Impact Factor: 30.39). 06/2006; 295(23):2742-51. DOI: 10.1001/jama.295.23.joc60075
Source: PubMed

ABSTRACT Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown.
To compare the differences in patient-reported outcomes, quality of life [QOL], and symptoms in Study of Tamoxifen and Raloxifene (STAR) participants by treatment assignment. DESIGN, SETTING, PARTICIPANTS, AND INTERVENTIONS: STAR was a double-blind, randomized phase 3 prevention trial designed to evaluate the relative efficacy of raloxifene vs tamoxifen in reducing the incidence of invasive breast cancer in high-risk postmenopausal women. Between July 1, 1999, and November 4, 2004, 19,747 participants were enrolled at centers throughout North America, with a median potential follow-up time of 4.6 years (range, 1.2-6.5 years). Patient-reported symptoms were collected from all participants using a 36-item symptom checklist. Quality of life was measured with the Medical Outcomes Study Short-Form Health Survey (SF-36), the Center for Epidemiologic Studies-Depression (CES-D), and the Medical Outcomes Study Sexual Activity Questionnaire in a substudy of 1983 participants, median potential follow-up 5.4 years (range, 4.6-6.0 years). Questionnaires were administered before treatment, every 6 months for 60 months and at 72 months.
Primary QOL end points were the SF-36 physical (PCS) and mental (MCS) component summaries.
Among women in the QOL analysis, mean PCS, MCS, and CES-D scores worsened modestly over the study's 60 months, with no significant difference between the tamoxifen (n = 973) and raloxifene (n = 1010) groups (P>.2). Sexual function was slightly better for participants assigned to tamoxifen (age-adjusted repeated measure odds ratio, 1.22%; 95% CI, 1.01-1.46). Of the women in the symptom assessment analyses, the 9769 in the raloxifene group reported greater mean symptom severity over 60 months of assessments than the 9743 in the tamoxifen group for musculoskeletal problems (1.15 vs 1.10, P = .002), dyspareunia (0.78 vs 0.68, P<.001), and weight gain (0.82 vs 0.76, P<.001). Women in the tamoxifen group reported greater mean symptom severity for gynecological problems (0.29 vs 0.19, P<.001), vasomotor symptoms (0.96 vs 0.85, P<.001), leg cramps (1.10 vs 0.91, P<.001), and bladder control symptoms (0.88 vs 0.73, P<.001).
No significant differences existed between the tamoxifen and raloxifene groups in patient-reported outcomes for physical health, mental health, and depression, although the tamoxifen group reported better sexual function. Although mean symptom severity was low among these postmenopausal women, those in the tamoxifen group reported more gynecological problems, vasomotor symptoms, leg cramps, and bladder control problems, whereas women in the raloxifene group reported more musculoskeletal problems, dyspareunia, and weight gain. Identifier: NCT00003906.

  • Source
    • "32. Phillips K. A., M. A. Jenkins, G. J. Lindeman, S. A. McLachlan, J. M. McKinley, P. C. Weideman, J. L. Hopper, M. L. Friedlander. 2006."
    [Show abstract] [Hide abstract]
    ABSTRACT: Neoadjuvant chemotherapy is the standard treatment approach for patients with locally advanced breast cancer, where primary disease downstaging clears improves operability. Previously unresectable disease may then be controlled by mastectomy, and some patients may even become eligible for lumpectomy. The disease downstaging benefits as well as the ability to determine chemosensitivity, have motivated expanded applications for neoadjuvant chemotherapy to include selected cases of early-stage breast cancer. In this setting, many women will become improved candidates for breast conservation surgery performed via smaller-volume lumpectomies. Optimal utilization of the neoadjuvant chemotherapy approach requires special attention by the surgeon regarding diagnostic biopsies (percutaneous needle biopsies are preferred); preoperative planning (insertion of radio-opaque clips to mark tumor bed prior to completion of chemotherapy response; careful imaging to determine extent of disease); and final surgical decision-making (including comprehensive preoperative imaging to decide between lumpectomy and mastectomy).
    Cancer treatment and research 02/2008; 141:79-98. DOI:10.1007/978-0-387-73161-2_6
  • Source
    • "32. Phillips K. A., M. A. Jenkins, G. J. Lindeman, S. A. McLachlan, J. M. McKinley, P. C. Weideman, J. L. Hopper, M. L. Friedlander. 2006."
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of breast-conserving therapy (BCT) using whole-breast irradiation (WBI) to eradicate residual disease following nonablative resection of breast cancer was one of the great success stories of twentieth-century oncology. Approximately 70-80% of patients with stage I or II invasive breast cancers are estimated to be potential candidates on technical grounds for BCT.
    Cancer treatment and research 02/2008; 141:135-48. DOI:10.1007/978-0-387-73161-2_9
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Quality of life (QoL) in cancer survivors is an important area of research. While data are available about QoL and breast cancer, there is a paucity of research regarding older breast cancer survivors. The purpose of this research was to examine QoL in older women with early stage breast cancer, within the first year of post-treatment survivorship. The specific aims of this study were to: 1) Describe the changes in overall QoL and the four QoL domains of Physical, Psychological, Social, and Spiritual well-being; 2) Examine the effects of a psychoeducational support intervention on QoL outcomes in older women; and 3) Describe nurses' perceptions of their interactions with older breast cancer survivors. A descriptive, longitudinal design was used to answer the research questions. Data for this study were drawn from the Breast Cancer Education Intervention (BCEI), a longitudinal psychoeducational support intervention for women with early stage breast cancer. Fifty women from the BCEI who were 65 years of age and older were included in this sample, of whom 24 were assigned to the Experimental (EX) Group and 26 were assigned to the Wait Control (WC) Group. Data were collected at three time points: baseline, three months, and six months after study entry. Measurement tools included the BCEI Demographics Form, the Quality of Life-Breast Cancer Survey (QoL-BC), and field notes of the BCEI Research Nurses. The QoL-BC survey is a 50-item scale that measures QoL in women with breast cancer. Descriptive statistics, Generalized Estimating Equation (GEE) methods and t-tests were used to answer research questions #1 and #2. Content analysis was used to answer research question #3. Subjects reported good overall QoL at baseline, but QoL declined over six months. Physical and Psychological well-being declined from baseline to six months later. Social well-being initially improved from baseline to three months but declined at six months. Spiritual well-being initially declined at three months and improved at six months. There was insufficient power to detect a difference in the effects of the BCEI Intervention between the two groups. However, the decline in overall QoL was less in the EX Group. Field notes focusing on nurses' perception of their interactions with older women revealed four themes. These themes include: continuing breast-related health, personal health issues, family health issues, and potential stressors. Results from this study suggest that: 1) changes in overall QoL and within the four QoL domains occur over time; 2) decline in overall QoL was lessened by the BCEI Intervention; and 3) concerns after treatment are both breast cancer and non-breast cancer related. Study findings can direct future research in the following areas: 1) identification of specific concerns within each QoL domain that could lead to an increase or decrease in well-being in older breast cancer survivors; 2) interventions tailored to the needs of older breast cancer survivors to maintain, improve, or lessen decline in QoL after treatment; and 3) reconceptualizing QoL in older breast cancer survivors to include non-cancer related factors.
Show more